Previous 10 | Next 10 |
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 Canada NewsWire HOUSTON and VANCOUVER, BC, July 31, 2020 HOUSTON and VANCOUVER, BC , July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a...
ESSA Pharma (NASDAQ: EPIX ) has priced its previously announced public offering of 7.1M shares at $6/share, for gross proceeds of ~$42.6M. The offer price represents a discount of 3.7% from the last close price of $6.23. More news on: ESSA Pharma Inc., Healthcare stocks news, , ...
VANCOUVER, BC and HOUSTON , July 28, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an...
ESSA Pharma Announces Proposed Public Offering of Common Shares Canada NewsWire VANCOUVER, BC and HOUSTON, July 28, 2020 VANCOUVER, BC and HOUSTON , July 28, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage ...
The first participant has been dosed in a 40-subject Phase 1 clinical trial evaluating ESSA Pharma's (NASDAQ: EPIX ) EPI-7386 in patients with metastatic castration-resistant prostate cancer who have failed to respond to standard-of-care therapies. More news on: ESSA Pharma Inc....
HOUSTON and VANCOUVER, BC , July 15, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical tr...
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II Canada NewsWire HOUSTON and VANCOUVER, BC, June 22, 2020 HOUSTON and VANCOUVER, BC , June 22, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
HOUSTON and VANCOUVER , May 27, 2020 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting...
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting Canada NewsWire HOUSTON and VANCOUVER, May 15, 2020 HOUSTON and VANCOUVER , May 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a...
News, Short Squeeze, Breakout and More Instantly...
ESSA Pharma to Present at the JonesHealthcare Seaside Summit Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de...
ESSA Pharma to Present at the Jefferies Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focus...